Collegium Enterprise Value Over E B I T D A from 2010 to 2024

COLL Stock  USD 33.40  0.27  0.80%   
Collegium Pharmaceutical Enterprise Value Over EBITDA yearly trend continues to be quite stable with very little volatility. Enterprise Value Over EBITDA may rise above 4.66 this year. From the period between 2010 and 2024, Collegium Pharmaceutical, Enterprise Value Over EBITDA regression line of its data series had standard deviation of  18.10 and standard deviation of  18.10. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
4.44167692
Current Value
4.66
Quarterly Volatility
18.09969484
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium main balance sheet or income statement drivers, such as Depreciation And Amortization of 156.7 M, Interest Expense of 87.5 M or Selling General Administrative of 97.6 M, as well as many exotic indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0 or PTB Ratio of 5.18. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
  
This module can also supplement Collegium Pharmaceutical's financial leverage analysis and stock options assessment as well as various Collegium Pharmaceutical Technical models . Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.

Latest Collegium Pharmaceutical's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Collegium Pharmaceutical over the last few years. It is Collegium Pharmaceutical's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collegium Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Collegium Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean0.34
Geometric Mean8.88
Coefficient Of Variation5,282
Mean Deviation12.94
Median(5.37)
Standard Deviation18.10
Sample Variance327.60
Range67.939
R-Value0.47
Mean Square Error274.32
R-Squared0.22
Significance0.08
Slope1.91
Total Sum of Squares4,586

Collegium Enterprise Value Over E B I T D A History

2024 4.66
2023 4.44
2022 43.18
2021 32.63
2020 13.84
2019 -24.76
2018 -22.6

About Collegium Pharmaceutical Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Collegium Pharmaceutical income statement, its balance sheet, and the statement of cash flows. Collegium Pharmaceutical investors use historical funamental indicators, such as Collegium Pharmaceutical's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Collegium Pharmaceutical investors may use each financial statement separately, they are all related. The changes in Collegium Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Collegium Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Collegium Pharmaceutical Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Collegium Pharmaceutical. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 4.44  4.66 

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Collegium Pharmaceutical using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out the analysis of Collegium Pharmaceutical Correlation against competitors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Collegium Stock analysis

When running Collegium Pharmaceutical's price analysis, check to measure Collegium Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collegium Pharmaceutical is operating at the current time. Most of Collegium Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Collegium Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collegium Pharmaceutical's price. Additionally, you may evaluate how the addition of Collegium Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Collegium Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
51.976
Earnings Share
2.51
Revenue Per Share
17.054
Quarterly Revenue Growth
0.001
Return On Assets
0.1056
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.